Christine M. Lovly, MD, PhD

Articles

Role of Rebiopsy at Disease Progression in EGFRm NSCLC

April 14th 2025

Panelists discuss how second-line therapy after osimertinib monotherapy depends on resistance mechanisms. If MET amplification, consider MET inhibitors plus EGFR tyrosine kinase inhibitors (TKIs). For C797S mutation, potential options include first- or third-generation EGFR TKI combinations. Chemotherapy remains a key fallback.

The Multidisciplinary Team’s Role in EGFRm NSCLC Management

April 14th 2025

Panelists discuss how a multidisciplinary team (MDT) plays a crucial role in managing EGFR-mutant non–small cell lung cancer (NSCLC) by integrating expertise from oncology, pathology, radiology, and surgery to optimize diagnosis, treatment, and monitoring. MDT collaboration ensures personalized, evidence-based care, enhancing patient outcomes.

Treatment Strategies to Manage AEs in EGFRm NSCLC

April 7th 2025

Panelists discuss how medical professionals have learned that proactive monitoring, early intervention, and patient-centered strategies are key to managing adverse events (AEs) in up-front combination therapy. Optimizing dosing, supportive care, and multidisciplinary coordination help maintain quality of life while ensuring treatment efficacy.

Clinical Factors to Consider When Choosing a Treatment Strategy

April 7th 2025

Panelists discuss how medical professionals assess patient characteristics such as molecular profile, disease burden, and central nervous system (CNS) involvement to tailor treatment. Monotherapy may be favored for lower burden or specific mutations, whereas combination therapy is chosen for aggressive disease or resistance risk.

FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach

March 31st 2025

Panelists discuss how the FLAURA, FLAURA2, and MARIPOSA trials have reshaped first-line therapy for EGFR-mutant non–small cell lung cancer. FLAURA established osimertinib as superior to first-generation tyrosine kinase inhibitors. FLAURA2 showed added benefit with chemotherapy. MARIPOSA highlighted amivantamab-lazertinib as a strong alternative, refining treatment choices.

Brief Overview of the Treatment Landscape of First-Line EGFRm NSCLC

March 31st 2025

Panelists discuss how the first-line treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC) primarily includes EGFR tyrosine kinase inhibitors, with osimertinib as the preferred monotherapy due to its efficacy and central nervous system penetration. Balancing efficacy and safety remain challenging, particularly regarding resistance and adverse effects. Although osimertinib monotherapy is widely used, combination strategies (eg, chemotherapy or antiangiogenic agents) are being explored to enhance outcomes. Treatment decisions are guided by mutation type, patient factors, and emerging clinical data.

BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC

May 31st 2024

Christine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.

Dr Lovly on the Investigation of BDTX-1535 in NSCLC

May 31st 2024

Christine M. Lovly, MD, PhD, discusses the investigation of the EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

x